These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38224415)

  • 41. Genetic-Guided Oral P2Y
    Ingraham BS; Farkouh ME; Lennon RJ; So D; Goodman SG; Geller N; Bae JH; Jeong MH; Baudhuin LM; Mathew V; Bell MR; Lerman A; Fu YP; Hasan A; Iturriaga E; Tanguay JF; Welsh RC; Rosenberg Y; Bailey K; Rihal C; Pereira NL
    JACC Cardiovasc Interv; 2023 Apr; 16(7):816-825. PubMed ID: 37045502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
    Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
    J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention.
    Zhang D; Li P; Qiu M; Liang Z; He J; Li Y; Han Y
    Atherosclerosis; 2024 Mar; 390():117395. PubMed ID: 38114408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
    Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
    Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y
    Cavallari LH; Limdi NA; Beitelshees AL; Lee JC; Duarte JD; Franchi F; Tuteja S; Giri J; Empey PE; Kreutz RP; Skaar TC; Allen JM; Coons JC; Gong Y; McDonough CW; Stevenson JM; Thomas CD; Johnson JA; Stouffer GA; Angiolillo DJ; Lee CR;
    Clin Pharmacol Ther; 2023 Mar; 113(3):615-623. PubMed ID: 36306392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
    Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenetics of P2Y
    Thomas CD; Williams AK; Lee CR; Cavallari LH
    Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y
    JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence.
    Gower MN; Ratner LR; Williams AK; Rossi JS; Stouffer GA; Lee CR
    Pharmgenomics Pers Med; 2020; 13():239-252. PubMed ID: 32821149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.
    Xiong R; Liu W; Chen L; Kang T; Ning S; Li J
    Int J Clin Exp Med; 2015; 8(8):13310-6. PubMed ID: 26550258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel.
    Chen YW; Liao YJ; Chang WC; Hsiao TH; Lin CH; Hsu CY; Liu TJ; Lee WL; Chen YM
    Front Cardiovasc Med; 2022; 9():994184. PubMed ID: 36072879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ticagrelor Aspirin vs Clopidogrel Aspirin in
    Wang A; Meng X; Tian X; Zuo Y; Bath PM; Li H; Xie X; Jing J; Lin J; Wang Y; Zhao X; Liu L; Li Z; Jiang Y; Xu J; Wang F; Chen W; Cao M; Li J; Wang Y
    Neurology; 2023 Jan; 100(5):e497-e504. PubMed ID: 36535779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention.
    Kaikita K; Ono T; Iwashita S; Nakayama N; Sato K; Horio E; Nakamura S; Tsujita K; Tayama S; Hokimoto S; Sakamoto T; Nakao K; Oshima S; Sugiyama S; Ogawa H
    J Atheroscler Thromb; 2014; 21(1):64-76. PubMed ID: 24088578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
    Stimpfle F; Karathanos A; Droppa M; Metzger J; Rath D; Müller K; Tavlaki E; Schäffeler E; Winter S; Schwab M; Gawaz M; Geisler T
    Thromb Res; 2014 Jul; 134(1):105-10. PubMed ID: 24856643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying
    Qian W; Chen L; Zhang L; Gao M; Wang C; Qian X; Yang C; Lin Y; Han Z
    J Thorac Dis; 2022 Jul; 14(7):2591-2601. PubMed ID: 35928614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
    Narasimhalu K; Ang YK; Tan DSY; De Silva DA; Tan KB
    Clin Drug Investig; 2020 Nov; 40(11):1063-1070. PubMed ID: 32959334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention.
    Zhang X; Yan L; Wang D; Li Y; Han L; Tian L; Liu H; Li Y
    Chin Med J (Engl); 2014; 127(14):2571-7. PubMed ID: 25043069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.